Estimating Utilities / Disutilities for High Risk Metastatic Hormone-Sensitive Prostate Cancer (MHSPC) and Treatment-Related Adverse Events

F Hall,Hm de Freitas,Cicely Kerr,T. Ito,Beenish Nafees,Andrew Lloyd,J Penton,Monica Hadi,T. P. Pham

Estimating Utilities / Disutilities for High Risk Metastatic Hormone-Sensitive Prostate Cancer (MHSPC) and Treatment-Related Adverse Events

2017

F Hall
Hm de Freitas
Cicely Kerr
T. Ito
Beenish Nafees
Andrew Lloyd
J Penton
Monica Hadi
T. P. Pham

Purpose To capture UK societal health utility values for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and the disutility associated with treatment-related adverse events (AEs) to inform future cost–utility analyses.

Keywords:

Androgen deprivation therapy
Prostate cancer
Adverse effect
Oncology
Hormone sensitive prostate cancer
Internal medicine
Docetaxel
Medicine
Intensive care medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations